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ABSTRACT: Expansion in production and commercial use of
nanomaterials increases the potential human exposure during the
lifecycle of these materials (production, use, and disposal).
Inhalation is a primary route of exposure to nanomaterials;
therefore it is critical to assess their potential respiratory hazard.
Herein, we developed a three-dimensional alveolar model
(EpiAlveolar) consisting of human primary alveolar epithelial
cells, fibroblasts, and endothelial cells, with or without macro-
phages for predicting long-term responses to aerosols. Following
thorough characterization of the model, proinflammatory and
profibrotic responses based on the adverse outcome pathway
concept for lung fibrosis were assessed upon repeated subchronic
exposures (up to 21 days) to two types of multiwalled carbon
nanotubes (MWCNTs) and silica quartz particles. We simulate occupational exposure doses for the MWCNTs (1−30 μg/cm2)
using an air−liquid interface exposure device (VITROCELL Cloud) with repeated exposures over 3 weeks. Specific key events
leading to lung fibrosis, such as barrier integrity and release of proinflammatory and profibrotic markers, show the
responsiveness of the model. Nanocyl induced, in general, a less pronounced reaction than Mitsui-7, and the cultures with
human monocyte-derived macrophages (MDMs) showed the proinflammatory response at later time points than those
without MDMs. In conclusion, we present a robust alveolar model to predict inflammatory and fibrotic responses upon
exposure to MWCNTs.
KEYWORDS: human primary cells, lung model, pulmonary fibrosis, multiwalled carbon nanotubes, air−liquid interface,
long-term repeated exposures
Progress in nanotechnology has led to increasedproduction of various types of nanomaterials withunique properties. Thermal stability, electrical con-
ductivity, and mechanical durability have made carbon
nanotubes (CNTs) one of the most widely used nanomaterials,
especially in the field of energy, electronics, and material
composites.1−5 The industrial use of CNTs could potentially
cause adverse biological and environmental impact throughout
their life cycle (i.e., from production to use and disposal). The
biopersistence and high aspect ratio of CNTs is particularly of
concern because exposure to these materials might induce
pulmonary pathologies (e.g., pulmonary inflammation, fibrosis,
mesothelioma, and other cancers) resembling those observed
with micrometer-sized asbestos fibers.6−8 A growing number of
animal tests demonstrate that exposure to multiwalled CNTs
(MWCNTs) potentially triggers airway injury, inflammation,
fibrosis, and granuloma formation.9−12 In particular, Mitsui-7
MWCNTs (henceforth referred to as Mitsui-7) have been
shown to induce progressive fibrotic response in mice.12−14
Pulmonary fibrosis can be induced in response to a specific
stimulus or as a consequence of the interactions of a substance
with alveolar epithelium.15,16 Nanomaterials can reach the
deepest regions of the lung (alveoli), depending on their
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physicochemical properties, and induce a cascade of cellular
responses17 that lead to pulmonary fibrosis.15,18−20 This
cascade of events can be organized into an adverse outcome
pathway (AOP) framework. AOPs provide a means to organize
existing knowledge about an adverse health effect starting with
a molecular initiating event (MIE) that triggers subsequent key
events (KEs) that occur at different levels of biological
organization, which ultimately lead to an adverse outcome
(AO). Organizing mechanistic information into an AOP helps
identify causally connected KEs and informs the choice of the
cell systems and assays best suited for investigating the
biological outcome.
An AOP describing the mechanism of pulmonary fibrosis is
being developed as a part of the Organisation for Economic
Co-operation and Development (OECD) AOP Development
Effort overseen by the Extended Advisory Group on Molecular
Screening and Toxicogenomics. Several putative AOPs for
pulmonary fibrosis with the potential MIE and KEs such as the
one shown in Supplementary Figure 1 have been described
previously.15,18,19,21 Of note here is that some of the KEs
presented in Supplementary Figure 1 could overlap or occur
simultaneously. Briefly, when a substance comes in contact
with cellular membranes (MIE), a number of danger markers,
called alarmins (an umbrella term for endogenous molecules
that signal tissue and cell damage), are released as a part of an
inflammatory response (KE1). The inflammatory response
includes release of proinflammatory cytokines (e.g., tumor
necrosis factor α (TNF-α), interleukin (IL)-1β, and IL-8) and
an influx of leukocytes to the alveolar space, which precedes
loss of alveolar barrier integrity (KE2). The purpose of the
inflammatory response is to clear the foreign material from the
tissue and to initiate repair, which is facilitated by growth
factors, such as transforming growth factor β (TGF-β). The
repair process involves proliferation and migration of epithelial
cells and differentiation of fibroblasts into myofibroblasts
(KE3), which produce extracellular matrix (ECM) compo-
nents (KE4) to repair the damage. Under physiological
conditions, inflammation is resolved and normal alveoli
structure and function is restored. However, in case of
exposure to high doses or persistent stimulus, the repair
process does not proceed properly. As a result, continued
inflammation and excessive fibroblast and myofibroblast
activation lead to increased ECM deposition and thickening
of alveolar walls and, ultimately, to pulmonary fibrosis (AO).
Choosing an assay or a battery of assays to measure the KEs
along an AOP can help in designing testing strategies to
predict complex outcomes such as pulmonary fibrosis.
While rodents have been used to characterize the whole lung
response, these experiments are time-consuming, expensive,
and of questionable human relevance and raise ethical
concerns. As a result, in vitro lung systems are being
increasingly used to investigate mechanisms of human toxicity
following particle exposure.22,23 One example of widely used in
vitro systems are three-dimensional (3D) reconstructed human
respiratory tissue models that are grown at the air−liquid
interface (ALI) and exhibit morphological and functional
characteristics similar to the in vivo microenvironment.
Reviews of in vitro models and recommendations on how to
apply them to predict complex human outcomes have been
described previously.22,24
In addition to choosing assays to measure specific KEs along
an AOP, it is critical to consider test substance concentration
and exposure methods that mimic human exposure conditions.
Many in vivo and in vitro studies were not designed to reflect a
real-life occupational setting where exposures are likely to
occur repeatedly over a long time frame.25 For example, several
studies have been carried out using relatively high material
doses, which may overwhelm normal defense mechanisms,
thus resulting in significant initial pulmonary inflamma-
tion.26−28 Additionally, many existing in vitro studies have
been conducted under submerged conditions, which are less
physiologically relevant than cells grown at the ALI since lung
tissue is exposed to air on its apical surface. ALI exposure
approaches provide a key strategy for mimicking inhalation
toxicity.29−33
The aim of this study was to design a test system of the
lower respiratory tract that could be used to assess the fibrotic
potential of substances. The use of an alveolar model in this
study was important because the small size of MWCNTs
allows them to penetrate deeply into the lung and probably
deposit in the alveoli. We developed, characterized, and tested
EpiAlveolar, a 3D reconstructed model of human alveolar
tissue consisting of alveolar epithelial cells, fibroblasts, and
endothelial cells, for its ability to recapitulate aspects of
pulmonary fibrosis. In addition, human monocyte-derived
macrophages (MDMs) were cocultured with the tissues to
examine their potential role in the proinflammatory and
profibrotic response. TGF-β was used as a positive fibrotic
control because of its involvement in the development of
fibrosis in different organs, disturbances of the homeostatic
microenvironment, promotion of cell activation, migration, and
invasion, and excessive extracellular matrix production.34
Dörntruper quartz (DQ12) particles were selected as a
positive control because they have been widely used in vitro
to stimulate the proinflammatory response35−37 and have been
shown to stimulate the development of fibrosis in vivo.38−40
Two types of MWCNTs, Mitsui-7 and Nanocyl, were chosen
as test materials because of the differences in their
physicochemical properties. They have also been shown to
induce the release of profibrotic mediators (TGF-β, platelet
derived-growth factor, and osteopontin)9,41−43 and up-regulate
transcriptional and histological markers of fibrosis in vitro.
Intratracheally instilled Nanocyl revealed a fibrotic response 28
days postexposure in mice.44 Mitsui-7 showed the potential to
cause pulmonary fibrosis in mice in several studies,12,13,45,46
investigating gene regulation,46 lung burden, and thickness of
connective tissue.12,13 In this study, the EpiAlveolar tissues
were exposed to test aerosolized materials using a VITRO-
CELL Cloud exposure system (VITROCELL Systems,
Germany) allowing a dose-controlled deposition of the
materials at the ALI. To mimic a realistic human exposure
scenario, repeated, long-term exposures were conducted at low
concentrations.
RESULTS AND DISCUSSION
Reliable testing approaches are needed to predict the risk, to
support the safe-by-design concept, and for sustainable
development of nanomaterials. Emerging tissue engineering
technologies have resulted in effective and efficient human-
relevant methods that align with the 3Rs principles.47 Human
cell-based models (e.g., 3D lung tissue models) and ALI
exposure devices have been developed during the past years,
allowing for direct aerosolization of nanomaterials onto the
surface of lung cells.33,48
The choice of test systems (i.e., cell types) and end points is
specific to the research question and can be optimized by
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considering the corresponding AOP. For example, the AOP for
pulmonary fibrosis as depicted in Supplementary Figure 1
shows the development of fibrosis (the AO) preceded by key
events (KEs), such as chronic inflammatory reactions, tissue
remodeling, and repair processes, which are prerequisites for
the development of the AO.
Submerged cell cultures using cell lines have revealed robust
results with clear pathways such as direct exposure of
fibroblasts to singlewalled CNTs increasing collagen type I
and III production49 or exposure of epithelial cells (BEAS-2B)
to singlewalled CNTs significantly increasing TGF-β release.50
To predict further profibrotic events, the EpiAlveolar model
was developed to mimic the in vivo human alveolar
microenvironment, which includes cell types relevant to
fibrosis, that is, human primary epithelial cells, endothelial
cells, and fibroblasts. Our approach can build on data from
submerged cell cultures by adding insights into further key
events such as barrier properties and extracellular matrix
tissues, two additional highly relevant KEs for the fibrotic
adverse outcome.
Characterization of EpiAlveolar Model. EpiAlveolar is
an in vitro organotypic model of the human alveolar tissue
composed of primary human alveolar epithelial cells and
pulmonary fibroblasts grown on the apical surface of a
Transwell insert and primary pulmonary endothelial cells
grown on the basal surface of the insert. The tissues were
cultured at the ALI to induce differentiation and to simulate in
vivo-like aerosol exposures.
The EpiAlveolar tissue model was evaluated for its ability to
mimic characteristics of the alveolar microenvironment in vivo.
The alveoli consist of an extremely thin epithelial layer
surrounded by a network of capillaries to enable gas exchange.
To evaluate if the overall morphology of the EpiAlveolar
tissues is similar, tissue cross sections were stained by
hematoxylin and eosin (H&E). Figure 1a shows that the
EpiAlveolar tissues are approximately 2−4 cell layers thick on
the apical surface with a thin monolayer of endothelial cells on
the basal surface. Furthermore, tissue sections were stained by
an epithelial marker, cytokeratin 19 (CK19), and a
mesenchymal cell marker, vimentin (VIM), to show the layer
of alveolar epithelial cells on top of the fibroblast (apical side)
and endothelial cell (basal side) layers (Figure 1b). The in vivo
alveolar epithelium consists of two cell types, type I (ATI) and
type II (ATII). The presence of both cell types was verified in
EpiAlveolar tissues by positive staining for cytokeratin 19
(CK19), an ATI marker, and cytokeratin 8 (CK8), an ATII
marker (Figure 1c). Transmission electron microscopy micro-
graphs confirmed the presence of lamellar bodies (Supple-
mentary Figure 2a), membrane-bound structures containing
stacked membranes of surfactant lipids.51 This result was
further verified by whole mount staining of the tissues for
expression of prosurfactant C (pSP-C), a critical feature of type
II alveolar epithelial cells (Figure 1d). Additionally, surface
tension of EpiAlveolar tissues, which is directly related to
surfactant production, was evaluated at day 2 (Supplementary
Figure 2b,c) as previously described in the literature.52−54 The
method relies on the fact that the diameter (d) of a deposited
droplet decreases with decreasing surface tension and vice
versa. EpiAlveolar tissues were tested in three biological
replicates (n = 3), while A549 cells served as assay control and
were measured only once (n = 1). The graph (Supplementary
Figure 2b) presents the relationship between drop ratio and
surface tension. Surface tension of EpiAlveolar tissues is
slightly higher than that measured in A549 cells,52 which could
Figure 1. Characterization of EpiAlveolar model. (a) Hematoxylin and eosin staining showing the thickness of the tissues, that is, 2−4 cell
layers thick on the apical surface and a thin monolayer of endothelial cells on the basal surface. (b) Tissue sections showing the cell location
within the tissue, that is, the layer of alveolar epithelial cells on top of the fibroblast (apical side) and endothelial cell (basal side) layers:
epithelial marker cytokeratin 19 (CK19, red), mesenchymal cell marker vimentin (VIM, green), and DAPI (blue) staining cell nuclei. (c)
Alveolar epithelial cell staining: ATI (CK19, red) and ATII cytokeratin 8 (CK8, green). (d) Whole mount staining of prosurfactant C (pSP-
C, red), a functional marker of ATII cells, and DAPI (blue) staining cell nuclei. (e) Immunofluorescsent staining for the epithelial tight
junction marker ZO-1 (red) and cell nuclei (DAPI, blue). (f) Transepithelial electrical resistance values for up to 42 days after tissue
development; data are presented as mean ± standard deviation, n = 3. Data obtained in Laboratory 1.
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be attributed to the fact that EpiAlveolar tissue consists of a
mixture of alveolar epithelial type I and II cells. Although the
measured surface tension is higher than seen in vivo,54 it is low
enough to keep regular shape of a drop (Supplementary Figure
2c), which confirms the presence of surfactants on the cellular
surface.52,53 Further quantification of the ratio of the cell types,
surface tension, and secretion of surfactant is ongoing. Having
demonstrated the presence and spatial organization of the
different alveolar cell types, we wanted to determine if the
EpiAlveolar tissues form a barrier, which is an important
function of the in vivo tissue and is not well developed when
using alveolar cell lines, such as A549 cells.55 Barrier function
was assessed by visualization of tight junctions (Figure 1e) and
measuring the transepithelial electrical resistance (TEER) over
time. A TEER value ≥300 Ω·cm2 was considered indicative of
an intact barrier based on previous manufacturer experiments
and recommendations. The mean TEER value of EpiAlveolar
tissues was highest the first week after completing differ-
entiation, decreased slightly, and then stabilized around 1000
Ω·cm2 (Figure 1f). TEER remained high for approximately one
month in culture, indicating that the tissue barrier remained
intact. This is important because it allows barrier integrity to
be assessed throughout long-term, repeated exposure experi-
ments. Following characterization of the EpiAlveolar model,
the tissues were challenged with different treatments and end
points were assessed related to the pulmonary fibrosis pathway
in humans as depicted in the AOP schematic (Supplementary
Figure 1).
Cellular Interaction of the Substance (MIE). Pulmonary
fibrosis is initiated by a variety of stimuli including persistent
infections, autoimmune reactions, allergic responses, chemical
insults, radiation, and tissue injury. MWCNTs have also
previously been shown to reach the lower respiratory tract and
cause lung fibrosis in vivo.12,42
It is worth mentioning that deposited materials on the
cellular surface can trigger a cascade of inflammatory mediator
and growth factor release, which activates fibroblast prolifer-
ation and extracellular matrix production, and therefore, uptake
by cells or translocation to cells located beneath the alveolar
epithelial layer is not the only condition for development of
pulmonary fibrosis. In addition, the barrier impairment could
increase the translocation of the materials across the alveolar
tissue, but with the herein used inserts having small pore sizes
(0.4 μm), this might be less probable.
Positive Controls Induced Proinflammatory and
Profibrotic Responses in the EpiAlveolar Model. Before
testing the effects of aerosol exposure to nanomaterials, it was
first necessary to demonstrate that a profibrotic phenotype
could be induced in the EpiAlveolar tissues. Toward this goal,
barrier function, tissue morphology, and profibrotic markers
Figure 2. Characterization of EpiAlveolar model response. (a) Transepithelial electrical resistance value for untreated tissues and tissues
upon exposure to TGF-β. Data are presented as mean ± standard deviation, n = 3. Data marked with # were considered statistically
significantly decreased (p < 0.05). (b) Hematoxylin and eosin staining showing the thickness of the untreated tissues, and nodule formation
and tissue contraction upon exposure to TGF-β. (c) Fluorescent micrographs of untreated and TGF-β treated tissues (scanned in two
different areas) presenting α-SMA (red) and fibronectin (green) expression, as well as nodule formation, upon exposure to TGF-β. Fibrotic
response of tissues upon exposures to TGF-β compared to untreated tissues: (d) fibronectin release; (e) COL1 release; data presented as
cumulative dose during 21 days, mean ± standard deviation, n = 3. Data marked with * were considered statistically significantly increased
(p < 0.05). Data obtained in Laboratory 1.
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were assessed following treatment with TGF-β, a known
chemical inducer of fibrosis.34,56−59 To ensure the reproduci-
bility of the result, characterization experiments were
conducted independently in three laboratories (MatTek
Corp. (Laboratory 1), Adolphe Merkle Institute (Laboratory
2), and Heriot-Watt University (Laboratory 3)).
After approximately 12 days of 10 ng/mL TGF-β treatment,
EpiAlveolar tissues began to contract away from the Transwell
insert and round up. This contraction resulted in reduced
TEER and, subsequently, complete loss (statistically significant
decrease, ∼10 Ω·cm2) of TEER at day 21 (Figure 2a, data from
Laboratory 1). Conversely, the untreated tissues maintained
barrier function for 21 days, with no significant difference
between the two untreated conditions (∼1000 Ω·cm2). Similar
to Laboratory 1, there was an evident drop in TEER upon
exposure to TGF-β compared to untreated cells at day 21 in
Laboratory 2 and at days 12 and 21 in Laboratory 3
(Supplementary Figure 3).
Homeostasis in the lung tissue depends on tightness of the
alveolar lining layer to provide a tight barrier against inhaled
foreign substances (e.g., microorganisms and particulate
matter).60 Treatment of EpiAlveolar with TGF-β abolished
the TEER after day 7. In comparison, untreated tissues
sustained a TEER of 1000 Ω·cm2, indicating an intact barrier
for the entire duration of the experiment (21 days). It was
previously shown that primary human ATI cells can develop
resistance between 1000 and 2000 Ω·cm2 when cultured in
vitro,51 which correlates with our results over the entire 3 week
period in culture at the ALI and was confirmed in three
independent laboratories. Treatment with MWCNTs and
DQ12 showed a slight decrease in TEER after 21 days, but
clear conclusions could not be drawn because of variability
between the readings.
EpiAlveolar tissues began showing a slightly denser ECM
around 7 days of treatment as shown in the H&E-stained cross
sections. By 12 days of treatment, large nodules of tissue were
visible, likely due to tissue contraction and increased ECM
deposition (data not shown, data from Laboratory 1). These
nodules were more prevalent at day 21 of TGF-β treatment,
and the centers of the nodules began to look somewhat
necrotic, perhaps due to their large size (Figure 3b).
Furthermore, TGF-β-treated tissues exhibited increased
expression of α smooth muscle actin (α-SMA, Figure 2c), a
major constituent of the contractile apparatus found in
Figure 3. Exposure scenario and characterization of investigated particles inside the VITROCELL Cloud exposure chamber. (a) MDM
seeding and exposure scenario. MDMs were seeded every Sunday (days (D) 1, 6, and 13) prior to starting each week of exposures.
EpiAlveolar tissues (with (+) and without (−) MDMs) were exposed every working day from Monday to Friday (5 times per week) for 3
consecutive weeks. For each experiment, the exposure chamber was wiped and the medium in the exposure chamber was changed between
exposures. (b) TEM micrographs of deposited particles (DQ12, Nanocyl, and Mitsui-7) on TEM grids placed at the bottom of the
VITROCELL Cloud exposure chamber. Upper line corresponds to deposited amount of particles in 1 day; lower line corresponds to overall
deposition during whole experiment, that is, after 3 weeks (15 days of exposures). Data obtained in Laboratory 2.
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myofibroblasts during wound healing and fibrosis, compared to
untreated cells. The contracted tissue morphology following
TGF-β was not evident in Laboratory 2 via laser scanning
microscopy (LSM), which could be due to the technical
difficulty of preserving the nodules during tissue preparation.
Laboratory 3 confirmed the results of Laboratory 1, seeing
contraction and nodule formation following 21 days of TGF-β
exposure (Supplementary Figure 3). It should be noted that
once the tissues started to contract, they were extremely prone
to detachment from the insert membrane.
TGF-β treatment of EpiAlveolar tissues induced another
hallmark of fibrosis: increased expression of ECM proteins,
such as fibronectin and collagen. Immunofluorescence staining
for fibronectin was increased in the EpiAlveolar tissues treated
with TGF-β for 21 days compared to untreated tissues (Figure
2c). Similarly, the concentration of fibronectin released into
the tissue culture media was significantly higher in the tissues
exposed to TGF-β compared to untreated tissues over all
experiments (Figure 2d). Secretion of type I, α-1 collagen
(COL1) was also significantly increased (p < 0.01) in the
media of TGF-β-treated tissues as cumulative dose over 21
days (Figure 2e). Taken together, these results show that the
positive control, TGF-β, was able to induce a profibrotic
response in EpiAlveolar tissues.
Characterization of MWCNT and DQ12 Exposures in
Laboratory 2. Following experiments confirming that the
EpiAlveolar tissues can be cultured long-term and are
responsive to inflammatory and fibrotic stimuli, the tissues
were evaluated in Laboratory 2 after subchronic exposure to
two MWCNTs, Mitsui-7 and Nanocyl, and the positive
control, silica quartz particles (DQ12).
The EpiAlveolar tissues were exposed to aerosolized
MWCNTs and DQ12 every working day from Monday to
Friday (five times per week) for three consecutive weeks to
mimic repeated occupational exposure. The scheme in Figure
3a depicts the days of exposures, sample collection, and media
changes. The basolateral media samples collected on days 1, 4,
7, 11, 14, 18, and 21 from three experiments were chosen for
analysis based on preliminary data from the first experiment.
In addition to choosing cell systems relevant to the target
biological site, it is critical to choose test concentrations that
are representative of realistic human exposures. In this study,
particle exposure was performed with the VITROCELL Cloud
system, which allows a dose-controlled and spatially uniform
deposition of aerosolized drugs61 or nanomaterials.62,63
EpiAlveolar tissues were exposed to repeated subchronic
exposures of MWCNTs and DQ12 particles at realistic
concentrations.
Prior to the cell exposures, the particles were carefully
characterized. To visualize dispersed particles, prior to further
exposures (nebulization), the liquid stock solutions of
MWCNTs and DQ12 were pipetted onto transmission
electron microscopy (TEM) grids and visualized using TEM
(Supplementary Figure 4). To investigate the material
deposited within the exposure chamber (VITROCELL
Cloud), a TEM grid was placed in the bottom of the exposure
chamber, and the deposited material was imaged by TEM
following one aerosol exposure (day 1 dose) and 15 exposures
(day 21 dose) (Figure 3b). The representative TEM images of
aerosolized particles (Mitsui-7, Nanocyl, and DQ12) present a
homogeneous and dose-dependent deposition comparing day
1 and day 21. Furthermore, Mitsui-7 appears as singlets or
small bundles of thicker tubes, while Nanocyl are shorter and
thinner tangled tubes. DQ12 showed single particle deposition
at day 1 and some aggregated particles at day 21, resulting
from repeated particle deposition. The aerosolized particles
were well distributed on the TEM grid surface because of
single droplet deposition, and it was observed that aerosoliza-
tion did not affect particle size or shape. These results
demonstrate that the VITROCELL Cloud system is suitable
for aerosol exposure of such materials and that the dispersed
materials demonstrate similar characteristics as the suspension
materials.
In addition to the qualitative assessment of deposited
material using TEM, the daily deposition was quantified using
a quartz crystal microbalance (QCM). It was not technically
possible to measure the repeated exposure doses (every
working day during 3 weeks) via QCM, because only one
device is available in our laboratory and several exposures of
different materials were performed daily. Therefore, each daily
exposure was measured, and the average deposition was
multiplied by number of exposures to estimate the weekly
(×5) or total (×15) deposition (Supplementary Figure 5).
Daily depositions of Mitsui-7 (2 different doses were
investigated) were therefore estimated to be ∼0.9 μg/cm2
and ∼2 μg/cm2, while total depositions increased to ∼13.5 μg/
cm2 and ∼29.6 μg/cm2. Nanocyl daily deposition was ∼1 μg/
cm2 and total deposition reached ∼15.2 μg/cm2, and DQ12
daily deposition was ∼0.2 μg/cm2 while total deposition
increased to ∼2.7 μg/cm2. The depositions were reproducible
among different wells within the chamber (∼4.3% as
previously shown61) as well as in a day-to-day manner.
The alveolar mass retention of a full working lifetime
exposure (45 years) to CNTs of different sizes was modeled
and calculated to be in the range of 12.4 to 46.5 μg/cm2.64
Herein, the maximal deposited concentration for Nanocyl was
15 μg/cm2, and those for Mitsui-7, two concentrations were
tested, resulting in 15 μg/cm2 and 30 μg/cm2, respectively,
within the 3 weeks of repeated exposures. The applied doses
are in the range of the reported lifetime human exposure to
MWCNTs;64 however, we still have to keep in mind that we
only assess the effects within 3 weeks. On the other hand, the
lowest applied concentration (1 μg/cm2) for Mitsui-7 and
Nanocyl corresponds with concentrations used in mice in
vivo.14,46 Moreover, the positive particle control DQ12
(crystalline quartz) has previously been used in vitro to
stimulate the proinflammatory response35−37 and in vivo to
stimulate the development of fibrosis.38,65 In our studies,
aerosolization of DQ12 resulted in an average deposited
concentration of ∼0.2 μg/cm2, and after repeated exposures,
the concentration was ∼2.7 μg/cm2. Applied concentrations
correspond to those used in previous in vitro studies that
resulted in a proinflammatory response.35,66 Furthermore,
these concentrations are comparable to in vivo experiments in
rats (3−30 mg/rat;38which corresponds to 0.6−6 μg/cm2,
deposition calculated based on ref 67).
Coculture of EpiAlveolar with Macrophages (Labo-
ratory 2). It has been demonstrated that macrophages
obtained from patients with lung fibrosis overproduce
proinflammatory cytokines and growth factors such as TNF-
α, IL-1, and TGF-β.68 Therefore, to understand the role of
macrophages in fibrosis development, we cocultured Epi-
Alveolar tissues with MDMs. Fresh MDMs were seeded each
week (schematic marking days of seeding in Figure 3a) on the
apical surface of the EpiAlveolar tissues ((+) MDMs), and the
response was compared to tissues without MDMs ((−)
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MDMs). MDM localization within the tissue was visualized via
anti-macrophage mannose receptor (also known as CD206)
staining using LSM. It was observed that MDMs are still
present in tissues after 21 days of exposures (Supplementary
Figure 6). Exposures to DQ12 and Mitsui-7 do not affect the
presence of MDMs (Supplementary Figure 5b,c) compared to
bovine serum albumin (BSA)-treated samples (Supplementary
Figure 5a), and they are located on the apical side of the
EpiAlveolar tissues (Supplementary Figure 6d).
Particle Interaction with EpiAlveolar and Their Effect
on Barrier Tightness (Laboratory 2). Fluorescence-
enhanced dark-field imaging was used to visualize the
distribution of Mitsui-7 in the EpiAlveolar tissues with (+)
and without (−) MDMs at D21. Representative 3D rendered
images (Supplementary Figure 7a,c) and xy projections
(Supplementary Figure 7b,d) show that the Mitsui-7 (white
arrows pointing to Mitsui-7) are associated with cells within
the EpiAlveolar tissues (+) and (−) MDMs. No difference in
Mitsui-7 locations was observed when comparing tissues (+)
and (−) MDMs. Since the tissues were grown on poly-
(ethylene terephthalate) (PET) membrane inserts, a strong
scattering of the insert pores resulted in artifacts (round-
shaped green objects), and Nanocyl and DQ12 particles did
not provide enough contrast to be visualized. Therefore,
further experiment was performed. Fixed tissues were scraped
using a cell scraper, resuspended in Kaiser’s glycerol, and
dropped on a glass slide. As-prepared samples were visualized
using fluorescence-enhanced dark-field imaging. We could
clearly confirm the presence of all tested materials with cells
extracted from the tissue (Figure 4). The cell type, however,
could not be determined by this method.
As barrier integrity is an important feature of epithelial cells,
tight junctions of EpiAlveolar tissues (−) MDMs were
visualized via zonula occludens 1, a tight junction protein,69
after 21 days of exposures (Figure 4). Exposures to DQ12 and
Nanocyl did not affect tight junction formation. Exposures to
Mitsui-7 affected formation of tight junctions; they appear
weaker. It is worth mentioning, that the surface of EpiAlveolar
is not flat and therefore we can observe patches with and
without tight junctions.
No Cytotoxicity Was Observed upon Material
Exposure (Laboratory 2). Cytotoxicity (lactate dehydrogen-
ase (LDH) release) was investigated in response to particle
(Mitsui-7, Nanocyl, and DQ12) exposures. No statistically
significant (p > 0.05) increase in LDH release into the
basolateral media was observed for all tested materials at days
7, 14, and 21 in both (+) and (−) MDMs tissues
(Supplementary Figure 8).
Cellular Morphology Was Significantly Altered upon
Exposure to TGF-β (Laboratory 2). EpiAlveolar tissues (−)
MDMs were treated with Mitsui-7 (daily deposition ∼2 μg/
cm2) and imaged using LSM to observe cell morphology. No
overt changes in epithelial cell or fibroblast morphology were
evident when compared to negative control (BSA treatment)
(Supplementary Figure 9). However, gaps or holes in the
endothelial cell layer were observed in the Mitsui-7-exposed
tissues. Exposures to DQ12 and Nanocyl showed a similar
pattern, but loss in endothelial cell continuity was less obvious
(data not shown). The TGF-β treatment [50 ng/mL] led to
changes in all cell types; they lost their regular shape, became
disorganized, and lost cell−cell contact, which caused
discontinuity of the cellular layer on both sides of the insert.
Release of Proinflammatory Mediators Was Signifi-
cantly Increased upon Exposures to Positive Controls,
DQ12, Nanocyl, or Mitsui-7 in Laboratory 2 (KE 1). TNF-
α, IL-1 family cytokines, IL-6, and IL-8 are proinflammatory
mediators that play important roles in local injury and
inflammatory reaction in development of human pulmonary
fibrosis.70,71 The release of these cytokines was assessed by
Enzyme Linked Immunosorbent Assay (ELISA) following
treatment of EpiAlveolar tissues with the positive controls
(TNF-α, lipopolysaccharide (LPS), or TGF-β) or with
particles (Figure 5 and Supplementary Figures 10 and 11).
Figure 4. Representative laser scanning microscopy images presenting tight junctions of tissue and enhanced dark-field microscopy images
showing interaction of investigated materials with cells. Tight junctions (left) and enhanced dark-field image (right) of tissue at day 21: (a)
untreated cells, (b) DQ12-treated, (c) Nanocyl-treated, and (d) Mitsui-7 (higher dose)-treated. Cyan represents nucleus; yellow represents
tight junctions (ZO-1). Data obtained in Laboratory 2.
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Tissues exposed to inflammatory positive controls (LPS and
TNF-α) showed general response following the proinflamma-
tory cascade;71 that is, TNF-α resulted in earlier response in
IL-8 release, while tissues treated with LPS showed an increase
in IL-8 production at later time points. No increase in TNF-α
and IL-6 release was observed at D21, interestingly IL-6 release
was significantly increased upon exposures to all positive
controls (LPS, TNF-α, and TGF-β) at most of the time points
(Days 1−18). On the other hand, tissues showed a statistically
significant increase in all investigated cytokines released after
exposure to Mitsui-7. In general, lower concentrations (∼1 μg/
cm2) induced a proinflammatory response at a later time point
(Day 11), while the higher concentration (∼2 μg/cm2)
induced a proinflammatory response as early as Day 1.
Nanocyl induced, in general, a less pronounced reaction than
Mitsui-7, a finding consistent with previously published results
investigating the response of 2D monocultures of epithelial
cells, fibroblasts, or macrophages in vitro.41 Similar results were
published also from in vivo study, where intratracheally instilled
Nanocyl showed a fibrotic response 28 days postexposure in
mice, which was less pronounced compared to longer
MWCNTs with higher diameter.44 The EpiAlveolar tissues
with added MDMs presented the proinflammatory response at
later time points (days 14 and 18), which could indicate that
MDMs initially reduced exposure to particles by clearance
from the ALI surface of the epithelial cells, but over time, they
released either the material or proinflammatory mediators,
which stimulate the epithelial cells, so that the response is
delayed. This indicates that MDMs are able to counterbalance
the immune reaction to a certain extent until the response
becomes uncontrolled. It has been reported from in vivo
studies in mice that an acute inflammatory phase response
started 1 day after exposure to 40 μg of Mitsui-7, peaked 7 days
after aspiration, and was always increased compared to
negative control for all investigated time points, up to 56
days.14 Although in this study the tissues showed a statistically
Figure 5. Tumor necrosis factor α (a−f) and interleukin 1β (g−l) release as a marker of proinflammatory response from tissues without
macrophages and with macrophages. Data are presented as relative to negative control (dashed line); untreated cells served as negative
control for positive control-treated cells (a, b, g, h), and DQ12 treated tissues (c, d, i, j), while BSA-treated cells served as negative control
for MWCNT-treated cells (e, f, k, l). Data are presented as mean ± standard deviation, (n = 3). Data marked as with * were considered
statistically significantly (p < 0.05) increased compared to negative control. Data obtained in Laboratory 2.
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significant increase in cytokine release after exposure to both
Mitsui-7 and Nanocyl, the response did not show a clear dose
or time dependence. Future studies could normalize ELISA
results to cell numbers to decrease the variability observed in
cytokine release.
In EpiAlveolar tissues (−) MDMs, the positive particle
control DQ12 induced significant TNF-α, IL-1β, and TGF-β
release. This response is comparable to a previous study, where
in vitro bronchial cells (without MDMs) from healthy
(nonasthmatic) donors developed a significant proinflamma-
tory (IL-8) response after 3 weeks of exposures while the cells
from asthmatic donors showed an increase in TGF-β release
after 5 weeks of repeated exposures to DQ12.35 An in vivo
study revealed that mice and rats exposed to DQ12 developed
chronic inflammation and intense lung fibrosis.38 Interestingly,
we observed only proinflammatory increase in IL-8 release at
day 1 and in IL-6 at day 21 upon exposures to DQ12 in the
presence of MDMs and at days 4 and 7 without MDMs.
The fluctuation of TNF-α and IL-1β release can be
compared with in vivo data investigating gene expression
upon exposure to carbon black nanoparticles. TNF-α receptor
superfamily was up-regulated at days 1, 3, 14, and 42, while IL-
1 receptor was up-regulated at 3 h and days 1, 2, and 14.72 As
gene expression and protein release do not happen at the same
time, we believe that correlation of our data with these results
is very important. However, further studies are needed to
confirm the correlation.
In summary, concentrations of overall release of TNF-α, IL-
1β, IL-6, and IL-8 were in the same range for both (+) and (−)
MDMs tissues (Supplementary Figures 13−16).
Profibrotic mediators are released after positive
control, DQ12, Nanocyl, and Mitsui-7 Exposures in
Laboratory 2 (KEs 1−4). Since chronic inflammation can
trigger a profibrotic response, we used ELISA to investigate
secretion of the profibrotic markers, TGF-β (Figure 6a−f),
fibronectin (Supplementary Figure 12), and COL1 (Figure
6g−l).
Figure 6. Transforming growth factor β (a−f) and collagen type 1α1 (g−l) release as a marker of profibrotic response from tissues without
macrophages and with macrophages. Data are presented as relative to negative control (dashed line); untreated cells served as negative
control for positive control-treated cells (a, b, g, h) and DQ12 treated tissues (c, d, i, j), while BSA-treated cells served as negative control for
MWCNT-treated cells (e, f, k, l). Data are presented as mean ± standard deviation, (n = 3). Data marked with * were considered statistically
significantly (p < 0.05) increased compared to negative control. Data obtained in Laboratory 2.
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Several in vivo studies reported that Mitsui-7 exposures
resulted in lung fibrosis12−14,73 as indicated by increased
thickness of connective tissue in the alveolar region. In vitro
investigation of 3D microtissues (combination of THP-1
macrophages, fibroblasts, and BEAS-2B epithelial cells)
showed changed microtissue morphology and significant
increase in gene expression of IL-1β and collagen types I
and III, upon exposure to Mitsui-7 after 4 and 7 days.74 This is
in agreement with our observations after treatment with TGF-
β, as gradual thickening and contraction of tissues was
observed at later time points (day 21); while Laboratory 2
observed only thickening of the tissues, Laboratories 1 and 3
observed also contraction of the tissue with nodule formation.
Tissue contraction led to detachment and loss of cells from the
membrane at day 14. An increase in α-SMA and fibronectin
was also observed after treatment with TGF-β at all tested
concentrations after 21 days. Similarly, the positive particle
control DQ12 induced significant increase in fibronectin
production at day 21, and in COL1 production occurred at
days 1, 14, and 21. EpiAlveolar tissues exposed to Nanocyl
resulted in a statistically significant increase in fibronectin
production at days 4 and 21 and in COL1 production at days
4, 7, and 21. COL1 and fibronectin release was significantly
increased at day 4 upon exposures to Mitsui-7 (at both lower
(∼1 μg/cm2) and higher (∼2 μg/cm2) concentrations).
Furthermore, COL1 production was increased at days 7 and
14 (at both lower (∼1 μg/cm2) and higher (∼2 μg/cm2)
concentrations), and at day 11 at lower (∼1 μg/cm2)
concentration. Fibronectin release was significantly increased
at days 14 and 18 (at the higher concentration) and days 18
and 21 (at the lower concentration).
All ELISA results (TNF-α, IL-1β, IL-6, IL-8, TGF-β,
fibronectin, and COL1) presented in absolute values
(including all investigated positive controls) can be seen in
Supplementary Figures 13−19. Statistical analysis of these data
is presented in Supplementary Tables 1−7.
Epithelial Barrier Integrity Decreased upon Exposure
to TGF-β but Was Stable upon DQ12 and MWCNT
Exposures (Laboratory 2). TEER was measured to assess
barrier integrity of the EpiAlveolar tissues following exposures
to test materials and controls. The TEER values remain high
up to day 21 in untreated EpiAlveolar tissues (+) and (−)
MDMs (Supplementary Figure 20). For the different material
treatments, TEER was only measured after day 21 to avoid the
potential removal of particles from the surface (Supplementary
Figure 19). Although a drop in TEER values upon exposure to
TGF-β can be observed, no statistically significant decrease (p
> 0.05) in TEER values was observed for both (−) and (+)
MDMs tissues, likely because of the high standard deviation of
untreated tissues. Future studies are needed to identify the
sources of variability in measuring TEER as it is one of the
important assays to assess barrier integrity.
To confirm TEER results, LSM xz projections were used to
assess the cellular layer integrity of EpiAlveolar tissues (+) and
(−) MDMs after 21 days of treatments with different materials.
During fibrosis, fibroblasts undergo excessive proliferation and
there is increased ECM deposition.75 The (−) MDMs tissues
show only a negligible increase in cellular layer thickness after
DQ12 (daily deposition ∼0.2 μg/cm2) and Mitsui-7 (daily
deposition ∼2 μg/cm2) treatment compared to BSA-treated
cells. Interestingly, the (+) MDMs tissues showed an increase
in the cellular layer thickness upon exposures to DQ12 (daily
deposition ∼0.2 μg/cm2) and Mitsui-7 (daily deposition ∼2
μg/cm2) compared to BSA-treated cells (Supplementary
Figure 21).
CONCLUSION
This study characterizes a 3D in vitro alveolar tissue model
comprised entirely of primary human cells to investigate its
ability to predict pulmonary fibrosis. We demonstrated that the
EpiAlveolar model recapitulates relevant lung phenotypes and
functions and is stable at the ALI for at least 3 weeks. Future
studies with EpiAlveolar could assess additional substances and
the effectiveness of antifibrotic agents and the impact of human
originated serum albumin to determine species-specific effects.
As with all studies, cause and effect analysis should be
considered for all the protocols used to identify potential
sources of variability (e.g., procedural variations or differences
between chemicals and assays based on their manufacturer).73
Additionally, transitioning the EpiAlveolar model to chemically
defined medium could increase the experimental reproduci-
bility. This careful consideration will help maximize inter- and
intralaboratory reproducibility and will be especially important
as this model is considered for incorporation into international
standards that may be used for regulatory testing.
METHODS
The handling and ability of the EpiAlveolar model to develop fibrosis
end points upon exposure to the positive control (TGF-β) was
confirmed in three laboratories. Afterward the particle studies were
only done in Laboratory 2, which had access to the VITROCELL
Cloud aerosolization system.
Characterization and Assessment of EpiAlveolar System
Conducted at MatTek Corporation (Laboratory 1). Human
Primary Cells Coculture Model MatTek EpiAlveolar. EpiAlveolar
(MatTek Corporation, Massachusetts, USA) is a new, commercially
available, organotypic model of the human alveolar tissue that is
grown at the ALI. To produce the tissues, human endothelial cells are
seeded onto the basal side of a microporous PET membrane insert
(pore size 0.4 μm, Corning Costar 3460). Then, primary human
fibroblasts and alveolar epithelial cells are seeded on the apical side of
the insert membrane. EpiAlveolar tissues are produced from primary
cells of lung origin from a disease-free, nonsmoking, 50 year old, male
Caucasian donor. Once the tissues were fully differentiated, they were
either shipped to Laboratory 2 for aerosol exposures or used at
Laboratory 1 for characterization and optimization of the TGF-β
control treatment. The tissues were fed every other day (Monday,
Wednesday, and Friday) with 5 mL of media (MatTek Corp, part no.
ALV-100-M250) in the basal compartment and 75 μL of media on
the apical surface, following the manufacturer’s protocol. When
beginning the experiments, tissues were switched from fully
supplemented media to media without the proprietary supplement
“X”, which the manufacturer has found to ablate the profibrotic effects
induced by TGF-β.
Transepithelial Electrical Resistance (TEER). TEER was assessed
at MatTek Corporation using an EVOM2 voltohmmeter and the
EndOhm-12 culture cup chamber (World Precision Instruments,
Florida, USA). Tissues were rinsed once with phosphate buffer saline
(PBS) containing calcium and magnesium (MatTek Corp., part no.
TEER-BUFFER) and transferred to the EndOhm-12 chamber
containing PBS (2 mL of PBS in the basal compartment and 0.5
mL in the apical compartment), and the raw resistance reading was
recorded after it had stabilized. Using Microsoft Excel, a background
reading of PBS alone was subtracted from the raw resistance values,
and the background subtracted value was multiplied by the surface
area (1.12 cm2). Two to four separate tissues were measured for each
condition at each time point, and the mean and standard deviation
across independent experiments was calculated. A TEER value greater
than or equal to 300 Ω·cm2 was considered to indicate an intact
barrier.
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Hematoxylin and Eosin and Immunofluorescene Staining of
EpiAlveolar Tissues. Tissues taken for histology and immunofluor-
escence were fixed overnight at room temperature in 10% buffered
formalin (Sigma-Aldrich, Switzerland). Tissues were then rinsed with
PBS, processed following standard practices, embedded in paraffin
wax, sectioned, and adhered to slides.76−79 Sections of each tissue
were stained by H&E to assess tissue morphology. An Olympus
VS120 Virtual Slide microscope (Olympus, Japan) was used to
acquire images of the stained slides.
Immunofluorescent staining was conducted for α-SMA, fibronectin,
CK8, CK19, and VIM. Slides were placed in 0.05% citraconic
anhydride in water, pH 7.4, and warmed for 45 min for antigen
retrieval. After cooling, the slides were rinsed with tris-buffered saline
(TBS) and blocked with 10% goat serum/1% BSA/TBS for 1 h at
room temperature. Primary antibodies (Abcam, MA, USA, and
Millipore, MA, USA) diluted in 1% BSA/0.1% Tween-20/TBS were
applied to the slides for 1 h in a humidified chamber at room
temperature. After this time, slides were washed, and the appropriate
secondary antibodies were applied (Invitrogen, California, USA) for 1
h. Nuclei were stained with DAPI (4′,6-diamidin-2-phenylindol), and
after additional wash steps, coverslips were mounted with
immunomount (Thermo Fisher Scientific Inc., MA, USA). All stained
slides were imaged using an Olympus IX81 confocal microscope with
Fluoview FV1000 (Olympus, Japan).
To determine the formation of tight junctions, EpiAlveolar tissues
were fixed in formalin for 10 min, then blocked with 10% goat serum
and 0.1% Triton X-100 for 1 h. Tissues were then incubated with
rabbit anti-ZO-1 (Zonula Occludens-1, Invitrogen no. 61-7300,
Carlsbad, CA, USA), diluted 1:100 in PBS + 1% BSA and 0.1%
Tween-20, for 2 h at RT. Tissues were rinsed in 10% goat serum +
Triton-X-100 and incubated in goat anti-rabbit Alexa Fluor 555
(Invitrogen) diluted 1:400 for 1 h at RT, followed by washing in PBS
and counterstaining with DAPI for 10 min. ZO-1 was imaged using an
Olympus IX81 microscope equipped with a FV1000 confocal system
and FV10-ASW software package.
Transmission Electron Microscopy (TEM) of EpiAlveolar
(Performed in Laboratory 2). In order to visualize lamellar bodies
present in EpiAlveolar tissues, the tissues were fixed in 2.5%
glutaraldehyde (Agar Scientific, Stansted, Essex, UK) in 0.15 M
HEPES (Fluka, Buchs, Switzerland) with an osmolarity of 670 mOsm
and adjusted to a pH of 7.35. The cells remained in the fixative at 4
°C for at least 24 h before being further processed.
The tissues were then washed with 0.15 M HEPES three times for
5 min, postfixed with 1% OsO4 (EMS, Hatfield, USA) in 0.1 M
sodium cacodylate buffer (Merck, Darmstadt, Germany) at 4 °C for 1
h. Thereafter cells were washed in 0.05 M maleic acid/NaOH buffer
three times for 5 min and dehydrated in 70%, 80%, and 96% ethanol
(Alcosuisse, Switzerland) for 15 min each at room temperature.
Subsequently, cells were immersed in 100% ethanol (Merck,
Darmstadt, Germany) three times for 10 min, and then they were
submerged in ethanol−Epon (1:1) overnight at room temperature.
The next day, cells were embedded in Epon (Fluka, Buchs,
Switzerland) and left to harden at 60 °C for 5 days. Ultrathin
sections (70−80 nm) were produced with an ultramicrotome UC6
(Leica Microsystems, Vienna, Austria), mounted on single slot copper
grids, and stained with uranyless and lead citrate with an ultrostainer
(Leica Microsystems, Vienna, Austria). TEM grids with mounted
sections were used without any further treatment. Representative
images were captured using a TEM (Fei Technai Spirit, Oregon,
USA) operating at 120 kV and equipped with a Veleta CCD camera
(Olympus, Japan). Images were recorded at a resolution of 2048 ×
2048 pixels.
Surface Tension of the EpiAlveolar Tissues at the ALI. The surface
tension was calculated based on a previously described protocol.54
Briefly, EpiAlveolar tissues were rinsed with PBS containing Ca and
Mg and then left at the ALI without apical media for 48 h before
measurement. Small droplets of dimethylphthalate/normal octanol
(Fluka) 4:1, v/v ratio, stained with 4 mg/mL of crystal violet (Sigma)
to facilitate visualization of the test droplets were dropped on the
apical side of EpiAlveolar tissues with a syringe. The method is based
on the fact that the diameter of the deposited droplet decreases with
decreasing surface tension and vice versa. Therefore, surface tension
of the hypophase was estimated by the ratio of the area (d) of the
deposited droplet on the apical surface of cells (either A549 cells as a
control52 or EpiAlveolar tissues) and the area (d0) of the droplet
measured prior to deposition (i.e., still attached to the micropipette,
Supplementary Figure 2c, referred as a hanging droplet). To measure
the droplet areas, photographs of the droplets were taken with a
digital camera. The surface tension was subsequently calculated using
a calibration curve (previously published for thin liquid substrates53)
to evaluate the relationship between the d/d0 ratio and the surface
tension of the cell surface.
Profibrotic Response to TGF-β. TGF-β was prepared according to
the manufacturer’s protocol (PeproTech, Inc., NJ, USA) at a stock
concentration of 10 μg/mL in citric acid/BSA/PBS and stored at −20
°C. A new aliquot of TGF-β stock was thawed and added to the
EpiAlveolar media fresh before each treatment.
Basolateral media samples were collected from the same individual
tissues before every media change. The samples were analyzed for
COL1, fibronectin, and TNF-α concentration using a Luminex kit
according to the manufacturer’s instructions (R&D Systems,
Minnesota, USA). All kit reagents were prepared as outlined in the
manufacturer’s protocol. Conditioned media samples were diluted at
1:50 for COL1 and fibronectin analysis and were left undiluted for
TNF-α analysis to fall within the range of the standard curve. The
media samples were mixed with the microparticle cocktail in duplicate
wells of 96-well plates and incubated for 2 h on an orbital shaker. The
samples were then washed on a magnetic plate washer to remove any
unbound microparticles. The bound particles were resuspended in the
kit’s biotin−antibody cocktail and incubated for 1 h on an orbital
shaker. Bound particles were washed, resuspended in Streptavidin-PE,
and incubated for 30 min on an orbital shaker. The bound particles
were given a final wash and resuspended in wash buffer to measure on
the Bio-Plex Multiplex system (Bio-Rad, California, USA). Data was
exported to Microsoft Excel before conducting statistical analyses.
Statistical Analysis. Statistical analyses were conducted using
GraphPad Prism 8 software. The mean and standard deviation were
calculated across replicate experiments. Statistically significant differ-
ences (p ≤ 0.05) were determined using a parametric one-way
analysis of variance (ANOVA) with Tukey’s HSD post hoc tests.
Three independent experiments (n = 3) were performed.
Investigation of EpiAlveolar Response to Particle Expo-
sures Conducted at the University of Fribourg (Laboratory 2).
Material Preparation. BSA (0.1% in ultrapure H2O) was sterile
filtered (0.2 μm pore size, Nalgene, Thermo Fisher Scientific,
Massachusetts, USA). BSA was used as the negative control for
MWCNT-treated cells and as dispersant for the MWCNTs. The
extremely hydrophobic properties of the CNTs, together with van der
Waals forces and high particle surface area, lead to particle
agglomeration in polar solvents.80 Therefore, dispersants (primarily
proteins) are used to prevent agglomeration and stabilize the
MWCNTs without substantial chemical surface modification.81−84
Both Mitsui-7 MWCNTs (Mitsui-7; Mitsui & Co, Japan) and
Nanocyl-7000 MWCNTs (Nanocyl; Nanocyl SA, Belgium; received
from European Commission Joint Research Centre, Italy, sample
JRCNM4000a), previously characterized within Nanogenotox proj-
ect,85 were dispersed in 0.1% BSA.41 Briefly, preweighed dry
MWCNT powder was heat sterilized at 100 °C overnight and
cooled, and a 50 μg/mL stock solution was prepared with 0.1% BSA.
This suspension was sonicated using an ultrasonic bath sonicator
(Elmasonic P30H, 100 W, 37 kHz, 30% amplitude, Elma
Schmidbauer GmbH, Germany) for 3 h with continuous shaking
and water cooling to disperse the MWCNTs and subsequently stored
at 4 °C until use.
Silica Dörntruper quartz particles (DQ12; composed of 87%
crystalline silica and amorphous silica with kaolinite impurities,
particle size ≤5 μm86), reported as a proinflammatory agent,87 were
used as reference material.
Unlike MWCNTs, DQ12 particles are not hydrophobic; therefore
they can be easily dispersed in ultrapure water. Therefore, DQ12
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particles were dispersed in ultrapure sterile filtered H2O at a
concentration of 100 μg/mL following the same sonication procedure
as for MWCNTs above.
All stock suspensions were sonicated for 1 h prior the exposure.
Material Characterization. Electron Microscopy. To investigate
the deposition of all tested materials, TEM 300 mesh carbon coated
copper grids were used. Prepared suspensions were pipetted onto the
TEM grids. Additionally, TEM grids were placed into the exposure
chamber prior to the exposure to visualize the aerosol deposited
particles and to compare their appearance with suspended particles.
TEM grids with deposited material were used without any further
treatment. Representative images were captured using a TEM (Fei
Technai Spirit, Oregon, USA) operating at 120 kV and equipped with
a Veleta CCD camera (Olympus, Japan). Images were recorded at a
resolution of 2048 × 2048 pixels.
Endotoxin Content. The endotoxin concentration in the
MWCNTs and DQ12 suspensions was measured using the Pierce
LAL Chromogenic Endotoxin Quantitation kit (Thermo Fisher
Scientific, Massachusetts, USA), following the manufacturer’s
instructions, and all suspensions were below 0.5 EU/mL. In order
to avoid the artifacts resulting from interference of the material with
an assay, three different concentrations of each particle suspension
were tested, and the results were compared among each other.
Coculturing EpiAlveolar with Human Monocyte-Derived Macro-
phages (MDMs). Peripheral human blood monocytes were isolated
from human blood buffy coats (Blood Donation Service, Bern
University hospital, Switzerland), as previously described by Lehmann
et al.88 with subsequent CD14+ MicroBead separation (Miltenyi
Biotec GmbH, Germany) according to the manufacturer’s protocol.
Fresh monocytes were frozen for future use at a density of 6 × 106
cells/mL in 90% fetal bovine serum (FBS, Gibco, Maryland, USA)
and 10% dimethyl sulfoxide serving as cryopreservative. The cells
were transferred to Nalgene Mr. Frosty Cryo 1 °C Freezing container
(−1 °C/min cooling rate, Thermo Fisher Scientific, Massachusetts,
USA) and placed in a −80 °C freezer, the vials were transferred to
liquid nitrogen tank the following day. Monocytes were later thawed
quickly in a 37 °C water bath and, before all the ice disappeared,
diluted with 10 volumes of warmed FBS and subsequently centrifuged
(200g, 5 min). The FBS supernatant was aspirated, and cell pellet was
resuspended in supplemented Roswell Park Memorial Institute 1640
(RPMI) medium (with 10% FBS, 1% penicillin/streptomycin
(corresponds to 100 units/mL penicillin and 100 μg/mL
streptomycin), and 2 mM L-glutamine (all Gibco, Maryland, USA))
and subsequently cultured for 6 days with the macrophage-colony
stimulating factor (M-CSF, [10 ng/mL]) prior assembling the
coculture at a density of 106 cells/mL. The cocultures (+) MDMs
were assembled by gently pipetting MDMs in supplemented RPMI
(0.5 mL/insert) on top of the EpiAlveolar tissues (cultured in MatTek
medium, 5 mL in the basal compartment) at a density of 5 × 104
MDMs/cm2 24 h prior to the first exposure. Tissues were transferred
to ALI conditions by removing media from apical side of the insert
and replacing the basal medium with 3 mL of MatTek cell culture
medium prior to the first exposure.
As MDMs do not proliferate and the lifetime in culture is limited,
fresh batches of MDMs from the same donor were reseeded every 7
days (on day 6 and day 13). Figure 3 shows the exposure scheme
together with days of seeding MDMs. The medium from the upper
compartment was removed the following morning (days 7 and 14)
prior to further exposures. Three independent repetitions of the
experiment were performed; therefore monocytes from three different
donors were used, that is, one donor per repetition.
Air−Liquid Interface Exposures to MWCNTs and DQ12. Tissues
were exposed at the ALI using the VITROCELL Cloud system.
Briefly, the exposure system consists of a nebulizer, an exposure
chamber, and a QCM (operated at 5 MHz (Mega Hertz), detection
limit 0.1 μg/cm2), allowing online measurements of the deposited
dose. For each nebulization, 200 μL of stock solution with 2 μL of
0.09% NaCl (NAAPREP physiological saline, GlaxoSmithKline,
France) was added to the nebulizer (a vibrating mesh with a span
of 2.5−6.0 μm volumetric mean diameter (for DQ12 sample) or 10
μm volumetric mean diameter (for all the other samples)), Aeroneb
Lab, Ireland). The vibrating perforated membrane at the neck of the
nebulizer generates the aerosol into the exposure chamber. Inside the
chamber, the aerosolized sample gently deposits onto the tissue
surfaces maintained at the ALI. The flow rate is ideal for the aerosol to
sufficiently mix to all sides of the chamber, hence resulting in uniform
droplet deposition. One single exposure, that is, daily exposure to
single particle dose, takes approximately 10−15 min.
Cells were exposed apically at the ALI daily and kept at 37 °C in
5% CO2 throughout the whole exposure period. Tissues were exposed
every working day (Monday−Friday) for 3 consecutive weeks. Media
was collected every Monday, Wednesday, and Friday (days 2, 4, 7, 9,
11, 14, 16, 18, and 21); furthermore the medium was also collected at
day 1.
Particle Interaction with EpiAlveolar. To investigate the
interaction of Mitsui-7 within the EpiAlveolar tissues, the samples
prepared for LSM analysis (see below) were also scanned using a
100× objective lens (numerical aperture 0.6 and 1.2) in Cytoviva dual
mode fluorescence-enhanced dark-field microscopy setup (Cytoviva
Inc., AL, USA). Because of strong scattering of the inserts, it was not
possible to visualize Nanocyl and DQ12, mostly due to their small
size. Therefore, the following experiment was performed.
Fixed tissues (cells on cell culture inserts, see below), stored in
PBS, were scraped off the insert using a cell scraper, centrifuged (at
10000 g) to remove excess PBS, resuspended in Kaiser’s glycerol
gelatin mounting medium (VWR, Switzerland) and dropped on a
glass slide. As-prepared samples were visualized using a 100×
objective lens (numerical aperture 0.6 and 1.2) in the Cytoviva dual
mode fluorescence-enhanced dark-field microscopy setup (Cytoviva
Inc., AL, USA) to investigate the interaction of the particles with the
cells. Using this method, it is not possible to determine the cell type
nor to distinguish between intracellular or cell membrane associated
particles.
Cytotoxicity. LDH release into the tissue culture media as a result
of cell membrane rupture is a well-known indicator of cytotoxicity.
The amount of LDH release was evaluated using a commercially
available LDH diagnostic kit (Roche Applied Science, Germany),
according to the manufacturer’s protocol. Each sample was measured
in triplicate. LDH values are presented relative to the untreated cells.
Cell cultures exposed apically to 0.2% Triton X-100 (100 μL,
submerged) for 24 h were used as a positive control for cell death.
Basal medium only was collected, therefore no interference of the
material with assay should occur. However, all materials were tested
for potential interference with the assay; no interference was observed
(data not shown).
Transepithelial Electrical Resistance (TEER). TEER measurement
is used to assess the cell barrier integrity. Tissues grown on membrane
inserts were washed with PBS with calcium and magnesium (TEER-
BUFFER, MatTek Corporation), and TEER was measured using
chop-stick Millipore equipment (Millicell ERS-2, EMD Millipore
Corporation, MA, USA). The TEER measurements were performed
on two defined spots of each membrane inserts (3 mL of TEER-
BUFFER in lower and 1 mL of TEER-BUFFER in upper
compartment). Resistance values of two empty (without cells)
membrane inserts (3 mL of TEER-BUFFER in lower and 1 mL of
TEER-BUFFER in upper compartment) were averaged (after two
independent sets of measurements) and subtracted from all the values
for cell layer samples. The absolute values were multiplied by growth
area of membrane inserts (1.12 cm2) and shown in [Ω·cm2].
Laser Scanning Microscopy (LSM). At the end of the experiment
(day 21), the tissues were fixed for 15 min in 4% paraformaldehyde in
PBS at room temperature, subsequently washed 3 times with PBS,
and stored in PBS at 4 °C.
Prior to immunofluorescent staining, samples were treated with 0.1
M glycine for 15 min and permeabilized with 0.2% Triton X-100 and
1% BSA in PBS for 15 min, both at room temperature. Antibodies
were diluted in 0.1% BSA in PBS and incubated for 2 h with primary
antibodies and then 2 h with secondary antibodies. The F-actin
cytoskeleton was stained with rhodamine phalloidin (Molecular
Probes, Thermo Fisher Scientific Inc., Massachusetts, USA) at 0.264
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μM, DAPI at 2 μg/mL in PBS stained nuclei, macrophages were
labeled using purified anti-human CD206 (Clone 15-2, Biolegend,
UK, 1:50 dilution) and goat anti-mouse AlexaFluor 488 (Abcam, UK;
1:100 dilution), and tight junctions were labeled using polyclonal
rabbit ZO-1 antibody (Thermo Fischer Scientific, Massachusetts,
USA) and goat anti-rabbit DY488 (Invitrogen, Thermo Fischer
Scientific, Massachusetts, USA). Following antibody incubation, cell
culture inserts were embedded in Kiser’s glycerol gelatin mounting
medium (VWR, Switzerland). Cell morphology was visualized via an
inverted confocal LSM 710 (Axio Observer.Z1, Carl Zeiss, Germany).
Image processing was conducted with IMARIS 3D restoration
software (Bitplane AG, Switzerland) or ImageJ.89
Proinflammatory Response to Positive Controls, MWCNTs, and
DQ12. IL-1β, TNF-α, and IL-8 release was assessed via ELISA, using
the commercially available DuoSet ELISA Development diagnostic kit
(R&D Systems, Switzerland), according to manufacturer’s protocol.
Cells treated both apically (100 μL, submerged) and basolaterally
with 100 ng/mL or 1 μg/mL LPS (from Escherichia coli, strain
O55:B5) served as positive controls for all three above-mentioned
cytokine analyses. Cells treated with 100 ng/mL or 1 μg/mL TNF-α
(ImmunoTools, Germany) served as the positive control for IL-8
assay, and cells treated with 10 ng/mL or 50 ng/mL TGF-β1
(ImmunoTools, Germany) served a positive control for IL-1β and
TNF-α release analysis. All positive controls were applied (apically
100 μL, submerged, and basolaterally) every Monday, Wednesday,
and Friday (i.e., days 0, 2, 4, 7, 9, 11, 14, 16, and 18) together with
media changes for all 3 weeks. The medium from the cell culture plate
was changed and collected for further analysis every Monday,
Wednesday, and Friday (days 2, 4, 7, 9, 11, 14, 16, and 18), and also
collected at day 1 and day 21. The collected medium (3 mL/tissue)
was pooled from 2 samples for ELISA analysis, except for TNF-α and
LPS treated samples, which were not pooled (only one tissue per
condition was analyzed).
Profibrotic Response to Positive Control, MWCNT, and DQ12
Exposures. TGF-β, fibronectin, and COL1 release into the basolateral
media was quantified using the respective ELISA DuoSet Develop-
ment diagnostic kit, following the manufacturer’s protocol. Based on
the supplier’s protocol, the TGF-β was pH activated immediately
before assaying. Cell cultures exposed both apically and basolaterally
to 10 ng/mL or 50 ng/mL TGF-β served as a positive control for
fibronectin and COL1 release analysis, cells treated with 100 ng/mL
or 1 μg/mL TNF-α served as the positive control for TGF-β and
fibronectin assay, and cells treated with 100 ng/mL or 1 μg/mL LPS
served as positive control for COL1 and TGF-β release analysis. All
positive controls were applied (apically 100 μL, submerged, and
basolaterally) every Monday, Wednesday, and Friday (i.e., days 0, 2, 4,
7, 9, 11, 14, 16, and 18), together with media changes for all 3 weeks.
The medium from cell culture plate was changed and collected for
further analysis every Monday, Wednesday, and Friday (days 2, 4, 7,
9, 11, 14, 16, and 18), and also collected at day 1 and day 21. The
collected medium (3 mL/tissue) was pooled from 2 samples for
ELISA analysis, except for TNF-α and LPS treated samples, which
were not pooled (only one tissue per condition was analyzed).
Statistical Analysis. The proinflammatory cytokine release upon
exposures to TGF-β, TNF-α, and LPS is presented as relative to
untreated cells. The cytokine release upon exposure to DQ12 is
presented as relative to untreated cells (DQ12 are dispersed in
ultrapure water), while MWCNT exposure results are presented as
relative to BSA-treated cells, as BSA was used as MWCNT dispersant.
For each data point, three independent experiments were performed,
and all data are presented as the mean ± standard deviation. Statistical
analysis was performed using GraphPad Prism 6 software (GraphPad
Software Inc., California, USA). A parametric one-way ANOVA with
subsequent Dunnett test was performed for TEER and LDH data
(Supplementary Figures 8 and 20). A parametric one-way analysis of
variance (ANOVA) with subsequent Dunnett’s test was performed for
each data point (repetition) separately and if at least two data points
out of three per treatment were statistically significant (p < 0.05), then
the treatment was considered as statistically significant (Figures 5 and
6 and Supplementary Figures 10−12; statistical results presented in
Supplementary Tables 1−7). A scheme depicting the statistical
analysis is presented in Supplementary Figure 22. Results were
considered significant if p < 0.05.
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Vitro Models of the Human Epithelial Airway Barrier to Study the
Toxic Potential of Particulate Matter. Expert Opin. Drug Metab.
Toxicol. 2008, 4, 1075−1089.
(24) Clippinger, A. J.; Allen, D.; Behrsing, H.; BeŕuBe,́ K. A.; Bolger,
M. B.; Casey, W.; DeLorme, M.; Gaca̧, M.; Gehen, S. C.; Glover, K.
ACS Nano www.acsnano.org Article
https://dx.doi.org/10.1021/acsnano.9b06860
ACS Nano XXXX, XXX, XXX−XXX
N
P.; Hayden, P.; Hinderliter, P.; Hotchkiss, J. A.; Iskandar, A.; Keyser,
B.; Luettich, K.; Ma-Hock, L.; Maione, A. G.; Makena, P.; Melbourne,
J.; et al. Pathway-Based Predictive Approaches for Non-Animal
Assessment of Acute Inhalation Toxicity. Toxicol. In Vitro 2018, 52,
131−145.
(25) Krug, H. F. Nanosafety ResearchAre We on the Right Track?
Angew. Chem., Int. Ed. 2014, 53, 12304−12319.
(26) Thurnherr, T.; Brandenberger, C.; Fischer, K.; Diener, L.;
Manser, P.; Maeder-Althaus, X.; Kaiser, J.-P.; Krug, H. F.; Rothen-
Rutishauser, B.; Wick, P. A Comparison of Acute and Long-Term
Effects of Industrial Multiwalled Carbon Nanotubes on Human Lung
and Immune Cells In Vitro. Toxicol. Lett. 2011, 200, 176−186.
(27) Wang, L.; Luanpitpong, S.; Castranova, V.; Tse, W.; Lu, Y.;
Pongrakhananon, V.; Rojanasakul, Y. Carbon Nanotubes Induce
Malignant Transformation and Tumorigenesis of Human Lung
Epithelial Cells. Nano Lett. 2011, 11, 2796−2803.
(28) Clift, M. J. D.; Endes, C.; Vanhecke, D.; Wick, P.; Gehr, P.;
Schins, R. P. F.; Petri-Fink, A.; Rothen-Rutishauser, B. A Comparative
Study of Different In Vitro Lung Cell Culture Systems to Assess the
Most Beneficial Tool for Screening the Potential Adverse Effects of
Carbon Nanotubes. Toxicol. Sci. 2014, 137, 55−64.
(29) Lenz, A. G.; Karg, E.; Lentner, B.; Dittrich, V.; Brandenberger,
C.; Rothen-Rutishauser, B.; Schulz, H.; Ferron, G. A.; Schmid, O. A
Dose-Controlled System for Air-Liquid Interface Cell Exposure and
Application to Zinc Oxide Nanoparticles. Part. Fibre Toxicol. 2009, 6,
32.
(30) Loret, T.; Peyret, E.; Dubreuil, M.; Aguerre-Chariol, O.;
Bressot, C.; le Bihan, O.; Amodeo, T.; Trouiller, B.; Braun, A.; Egles,
C.; Lacroix, G. Air-Liquid Interface Exposure to Aerosols of Poorly
Soluble Nanomaterials Induces Different Biological Activation Levels
Compared to Exposure to Suspensions. Part. Fibre Toxicol. 2016, 13,
58.
(31) Kim, J. S.; Peters, T. M.; O’Shaughnessy, P. T.; Adamcakova-
Dodd, A.; Thorne, P. S. Validation of an In Vitro Exposure System for
Toxicity Assessment of Air-Delivered Nanomaterials. Toxicol. In Vitro
2013, 27, 164−173.
(32) Polk, W. W.; Sharma, M.; Sayes, C. M.; Hotchkiss, J. A.;
Clippinger, A. J. Aerosol Generation and Characterization of Multi-
Walled Carbon Nanotubes Exposed to Cells Cultured at the Air-
Liquid Interface. Part. Fibre Toxicol. 2015, 13, 20.
(33) Lacroix, G.; Koch, W.; Ritter, D.; Gutleb, A. C.; Larsen, S. T.;
Loret, T.; Zanetti, F.; Constant, S.; Chortarea, S.; Rothen-Rutishauser,
B.; Hiemstra, P. S.; Frejafon, E.; Hubert, P.; Gribaldo, L.; Kearns, P.;
Aublant, J.-M.; Diabate,́ S.; Weiss, C.; de Groot, A.; Kooter, I. Air−
Liquid Interface In VitroModels for Respiratory Toxicology Research:
Consensus Workshop and Recommendations. Appl. In Vitro Toxicol.
2018, 4, 91−106.
(34) Fernandez, I. E.; Eickelberg, O. The Impact of TGF-beta on
Lung Fibrosis: From Targeting to Biomarkers. Proc. Am. Thorac. Soc.
2012, 9, 111−116.
(35) Chortarea, S.; Barosova, H.; Clift, M. J. D.; Wick, P.; Petri-Fink,
A.; Rothen-Rutishauser, B. Human Asthmatic Bronchial Cells Are
More Susceptible to Subchronic Repeated Exposures of Aerosolized
Carbon Nanotubes at Occupationally Relevant Doses Than Healthy
Cells. ACS Nano 2017, 11, 7615−7625.
(36) Endes, C.; Schmid, O.; Kinnear, C.; Mueller, S.; Camarero-
Espinosa, S.; Vanhecke, D.; Foster, E. J.; Petri-Fink, A.; Rothen-
Rutishauser, B.; Weder, C.; Clift, M. J. D. An In Vitro Testing Strategy
towards Mimicking the Inhalation of High Aspect Ratio Nano-
particles. Part. Fibre Toxicol. 2014, 11, 40.
(37) Beyeler, S.; Chortarea, S.; Rothen-Rutishauser, B.; Petri-Fink,
A.; Wick, P.; Tschanz, S. A.; von Garnier, C.; Blank, F. Acute Effects
of Multi-Walled Carbon Nanotubes on Primary Bronchial Epithelial
Cells from COPD Patients. Nanotoxicology 2018, 12, 699−711.
(38) Barbarin, V.; Nihoul, A.; Misson, P.; Arras, M.; Delos, M.;
Leclercq, I.; Lison, D.; Huaux, F. The Role of Pro- and Anti-
Inflammatory Responses in Silica-Induced Lung Fibrosis. Respir. Res.
2005, 6, 112.
(39) Blake, T. L.; DiMatteo, M.; Antonini, J. M.; McCloud, C. M.;
Reasor, M. J. Subchronic Pulmonary Inflammation and Fibrosis
Induced by Silica in Rats Are Attenuated by Amiodarone. Exp. Lung
Res. 1996, 22, 113−131.
(40) Carter, J. M.; Driscoll, K. E. The Role of Inflammation,
Oxidative Stress, and Proliferation in Silica-Induced Lung Disease: A
Species Comparison. J. Environ. Pathol., Toxicol. Oncol. 2001, 20, 33−
43.
(41) Chortarea, S.; Zerimariam, F.; Barosova, H.; Septiadi, D.; Clift,
M.; Petri-Fink, A.; Rothen-Rutishauser, B. Profibrotic Activity of
Multi-Walled Carbon Nanotubes upon Prolonged Exposures in
Different Human Lung Cell Types. Appl. In Vitro Toxicol. 2019, 5, 47.
(42) Vietti, G.; Ibouraadaten, S.; Palmai-Pallag, M.; Yakoub, Y.;
Bailly, C.; Fenoglio, I.; Marbaix, E.; Lison, D.; van den Brule, S.
Towards Predicting the Lung Fibrogenic Activity of Nanomaterials:
Experimental Validation of an In Vitro Fibroblast Proliferation Assay.
Part. Fibre Toxicol. 2013, 10, 52.
(43) van Berlo, D.; Wilhelmi, V.; Boots, A. W.; Hullmann, M.;
Kuhlbusch, T. A. J.; Bast, A.; Schins, R. P. F.; Albrecht, C. Apoptotic,
Inflammatory, and Fibrogenic Effects of Two Different Types of
Multi-Walled Carbon Nanotubes in Mouse Lung. Arch. Toxicol. 2014,
88, 1725−1737.
(44) Poulsen, S. S.; Saber, A. T.; Williams, A.; Andersen, O.; Købler,
C.; Atluri, R.; Pozzebon, M. E.; Mucelli, S. P.; Simion, M.; Rickerby,
D.; Mortensen, A.; Jackson, P.; Kyjovska, Z. O.; Mølhave, K.;
Jacobsen, N. R.; Jensen, K. A.; Yauk, C. L.; Wallin, H.; Halappanavar,
S.; Vogel, U. MWCNTs of Different Physicochemical Properties
Cause Similar Inflammatory Responses, but Differences in Transcrip-
tional and Histological Markers of Fibrosis in Mouse Lungs. Toxicol.
Appl. Pharmacol. 2015, 284, 16−32.
(45) Snyder-Talkington, B. N.; Dymacek, J.; Porter, D. W.; Wolfarth,
M. G.; Mercer, R. R.; Pacurari, M.; Denvir, J.; Castranova, V.; Qian,
Y.; Guo, N. L. System-Based Identification of Toxicity Pathways
Associated with Multi-Walled Carbon Nanotube-Induced Patholog-
ical Responses. Toxicol. Appl. Pharmacol. 2013, 272, 476−489.
(46) Snyder-Talkington, B. N.; Dong, C.; Porter, D. W.; Ducatman,
B.; Wolfarth, M. G.; Andrew, M.; Battelli, L.; Raese, R.; Castranova,
V.; Guo, N. L.; Qian, Y. Multiwalled Carbon Nanotube-Induced
Pulmonary Inflammatory and Fibrotic Responses and Genomic
Changes Following Aspiration Exposure in Mice: A 1-Year
Postexposure Study. J. Toxicol. Environ. Health, Part A 2016, 79,
352−366.
(47) Flecknell, P. Replacement, Reduction, Refinement. ALTEX -
Alternatives to animal experimentation 2002, 19, 73−78.
(48) Paur, H. R.; Cassee, F. R.; Teeguarden, J.; Fissan, H.; Diabate,
S.; Aufderheide, M.; Kreyling, W. G.; Hanninen, O.; Kasper, G.;
Riediker, M.; Rothen-Rutishauser, B.; Schmid, O. In-Vitro Cell
Exposure Studies for the Assessment of Nanoparticle Toxicity in the
Lung-A Dialog between Aerosol Science and Biology. J. Aerosol Sci.
2011, 42, 668−692.
(49) Wang, L.; Mercer, R. R.; Rojanasakul, Y.; Qiu, A.; Lu, Y.;
Scabilloni, J. F.; Wu, N.; Castranova, V. Direct Fibrogenic Effects of
Dispersed Single-Walled Carbon Nanotubes on Human Lung
Fibroblasts. J. Toxicol. Environ. Health, Part A 2010, 73, 410−422.
(50) Wang, X.; Lee, J. H.; Li, R.; Liao, Y. P.; Kang, J.; Chang, C. H.;
Guiney, L. M.; Mirshafiee, V.; Li, L.; Lu, J.; Xia, T.; Hersam, M. C.;
Nel, A. E. Toxicological Profiling of Highly Purified Single-Walled
Carbon Nanotubes with Different Lengths in the Rodent Lung and
Escherichia Coli. Small 2018, 14, 1703915.
(51) Fuchs, S.; Hollins, A.; Laue, M.; Schaefer, U.; Roemer, K.;
Gumbleton, M.; Lehr, C.-M. Differentiation of Human Alveolar
Epithelial Cells in Primary Culture: Morphological Characterization
and Synthesis of Caveolin-1 and Surfactant Protein-C. Cell Tissue Res.
2003, 311, 31−45.
(52) Blank, F.; Rothen-Rutishauser, B. M.; Schurch, S.; Gehr, P. An
Optimized In Vitro Model of the Respiratory Tract Wall to Study
Particle Cell Interactions. J. Aerosol Med. 2006, 19, 392.
(53) Ohlinger, K.; Kolesnik, T.; Meindl, C.; Galle, B.; Absenger-
Novak, M.; Kolb-Lenz, D.; Frohlich, E. Air-Liquid Interface Culture
ACS Nano www.acsnano.org Article
https://dx.doi.org/10.1021/acsnano.9b06860
ACS Nano XXXX, XXX, XXX−XXX
O
Changes Surface Properties of A549 Cells. Toxicol. In Vitro 2019, 60,
369−82.
(54) Im Hof, V.; Gehr, P.; Gerber, V.; Lee, M. M.; Schürch, S. In
Vivo Determination of Surface Tension in the Horse Trachea and In
Vitro Model Studies. Respir. Physiol. 1997, 109, 81−93.
(55) Srinivasan, B.; Kolli, A. R.; Esch, M. B.; Abaci, H. E.; Shuler, M.
L.; Hickman, J. J. TEER Measurement Techniques for In Vitro Barrier
Model Systems. J. Lab. Autom. 2015, 20, 107−126.
(56) Yue, X.; Shan, B.; Lasky, J. A. TGF-β: Titan of Lung
Fibrogenesis. Curr. Enzyme Inhib. 2010, 6, 67.
(57) Xu, Q.; Norman, J. T.; Shrivastav, S.; Lucio-Cazana, J.; Kopp, J.
B. In Vitro Models of TGF-Beta-Induced Fibrosis Suitable for High-
Throughput Screening of Antifibrotic Agents. Am. J. Physiol.: Renal
Physiol. 2007, 293, F631−640.
(58) Biernacka, A.; Dobaczewski, M.; Frangogiannis, N. G. TGF-
Beta Signaling in Fibrosis. Growth Factors 2011, 29, 196−202.
(59) Walton, K. L.; Johnson, K. E.; Harrison, C. A. Targeting TGF-
Beta Mediated SMAD Signaling for the Prevention of Fibrosis. Front.
Pharmacol. 2017, 8, 461.
(60) Ochs, M.; Weibel, E. R. Scientific Basis of Lung Function in
Health and Disease. In Fishman’s Pulmonary Diseases and Disorders,
5e; Grippi, M., Elias, J., Fishman, J., Kotloff, R., Pack, A., Senior, R.,
Siegel, M., Eds.; McGraw-Hill Education: USA, 2008, Part 2.
(61) Lenz, A. G.; Stoeger, T.; Cei, D.; Schmidmeir, M.; Semren, N.;
Burgstaller, G.; Lentner, B.; Eickelberg, O.; Meiners, S.; Schmid, O.
Efficient Bioactive Delivery of Aerosolized Drugs to Human
Pulmonary Epithelial Cells Cultured in Air−Liquid Interface
Conditions. Am. J. Respir. Cell Mol. Biol. 2014, 51, 526−535.
(62) Drasler, B.; Kucki, M.; Delhaes, F.; Buerki-Thurnherr, T.;
Vanhecke, D.; Korejwo, D.; Chortarea, S.; Barosova, H.; Hirsch, C.;
Petri-Fink, A.; Rothen-Rutishauser, B.; Wick, P. Single Exposure to
Aerosolized Graphene Oxide and Graphene Nanoplatelets Did Not
Initiate an Acute Biological Response in a 3D Human Lung Model.
Carbon 2018, 137, 125−135.
(63) Durantie, E.; Vanhecke, D.; Rodriguez-Lorenzo, L.; Delhaes, F.;
Balog, S.; Septiadi, D.; Bourquin, J.; Petri-Fink, A.; Rothen-
Rutishauser, B. Biodistribution of Single and Aggregated Gold
Nanoparticles Exposed to the Human Lung Epithelial Tissue Barrier
at the Air-Liquid Interface. Part. Fibre Toxicol. 2017, 14, 49.
(64) Gangwal, S.; Brown, J. S.; Wang, A.; Houck, K. A.; Dix, D. J.;
Kavlock, R. J.; Hubal, E. A. C. Informing Selection of Nanomaterial
Concentrations for ToxCast In Vitro Testing Based on Occupational
Exposure Potential. Environ. Health Perspect. 2011, 119, 1539−1546.
(65) Huaux, F.; Louahed, J.; Hudspith, B.; Meredith, C.; Delos, M.;
Renauld, J.-C.; Lison, D. Role of Interleukin-10 in the Lung Response
to Silica in Mice. Am. J. Respir. Cell Mol. Biol. 1998, 18, 51−59.
(66) Chortarea, S.; Clift, M. J. D.; Vanhecke, D.; Endes, C.; Wick, P.;
Petri-Fink, A.; Rothen-Rutishauser, B. Repeated Exposure to Carbon
Nanotube-Based Aerosols Does Not Affect the Functional Properties
of a 3D Human Epithelial Airway Model. Nanotoxicology 2015, 9,
983−993.
(67) Pinkerton, K. E.; Gehr, P.; Castañeda, A.; Crapo, J. D.
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